CC
CLDX icon

Commodore Capital’s Celldex Therapeutics CLDX Stock Holding History

Commodore Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.2M Sell
1,350,000
-1,346,616
-50% -$43.5M 2.99% 13
2026
Q1 		$85.5M Buy
2,696,616
+131,616
+5% +$3.59M 4.95% 7
2025
Q4 		$69.7M Sell
2,565,000
-463,335
-15% -$12.2M 4.64% 8
2025
Q3 		$78.3M Sell
3,028,335
-421,665
-12% -$9.77M 3.82% 10
2025
Q2 		$70.2M Buy
3,450,000
+250,000
+8% +$4.87M 4.96% 6
2025
Q1 		$58.1M Buy
+3,200,000
New +$71.5M 4.28% 10
2024
Q4 		– Sell
-1,618,937
Closed -$55M – 36
2024
Q3 		$55M Buy
1,618,937
+193,937
+14% +$7.39M 3.44% 12
2024
Q2 		$52.7M Buy
1,425,000
+558,532
+64% +$21.1M 3.6% 9
2024
Q1 		$36.4M Buy
866,468
+164,501
+23% +$6.75M 2.43% 14
2023
Q4 		$27.8M Sell
701,967
-4,698
-0.7% -$138K 2.43% 16
2023
Q3 		$19.4M Buy
706,665
+75,000
+12% +$2.35M 2.27% 16
2023
Q2 		$21.4M Buy
631,665
+135,842
+27% +$4.58M 2.41% 14
2023
Q1 		$17.8M Hold
495,823
– – 2.72% 13
2022
Q4 		$22.1M Sell
495,823
-42,989
-8% -$1.53M 3.33% 10
2022
Q3 		$15.1M Hold
538,812
– – 2.44% 14
2022
Q2 		$14.5M Buy
538,812
+297,613
+123% +$8.64M 3.07% 13
2022
Q1 		$8.21M Buy
+241,199
New +$7.71M 1.83% 18
2021
Q4 		– Sell
-248,207
Closed -$13.4M – 27
2021
Q3 		$13.4M Sell
248,207
-75,230
-23% -$3.53M 3.53% 13
2021
Q2 		$10.8M Sell
323,437
-46,514
-13% -$1.28M 3.77% 11
2021
Q1 		$7.62M Buy
369,951
+13,520
+4% +$310K 3.04% 15
2020
Q4 		$6.25M Buy
+356,431
New +$6.41M 3.4% 15

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Commodore Capital's CLDX Position: Q2 2026 in Review

Commodore Capital reduced its Celldex Therapeutics (CLDX) stake by 50% in Q2 2026, selling an estimated $43.5M and leaving 1,350,000 shares worth $50.2M. The position accounts for 2.99% of the portfolio, ranked #13.

Commodore Capital first reported a position in CLDX in Q4 2020 and has held it in 21 quarters since. The position peaked at $85.5M in Q1 2026. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Commodore Capital held 1,350,000 shares of Celldex Therapeutics worth $50.2M as of Q2 2026.
  • Commodore Capital sold 1,346,616 Celldex Therapeutics shares in Q2 2026, an estimated $43.5M.
  • Celldex Therapeutics made up 2.99% of Commodore Capital's portfolio in Q2 2026, its #13 holding.
  • Commodore Capital first reported a position in Celldex Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Commodore Capital's Celldex Therapeutics position peaked at $85.5M in Q1 2026.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.